Ethyl 2-[[4-methoxybenzenesulfonyl](2-[4-morpholino]ethyl)amino]acetate | 177702-11-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ethyl 2-[[4-methoxybenzenesulfonyl](2-[4-morpholino]ethyl)amino]acetate
• 英文别名: Ethyl 2-[(4-methoxyphenyl)sulfonyl-(2-morpholin-4-ylethyl)amino]acetate
• CAS: 177702-11-3
• 化学式: C₁₇H₂₆N₂O₆S
• 分子量: 386.469
• InChiKey: MLHBIOFDFVGDKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  93.8
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  Ethyl 2-[[4-methoxybenzenesulfonyl](2-[4-morpholino]ethyl)amino]acetate 在 盐酸羟胺 、 sodium 作用下， 以 乙醇 为溶剂， 生成 N-hydroxy-2-[[4-methoxybenzenesulfonyl](2-[4-morpholino]ethyl)amino]acetamide
  参考文献：
  名称：

  Arylsulfonamido-substituted hydroxamix acids

  摘要：

  公开的是式I的化合物##STR1##其中R、R.sub.1、R.sub.2和Ar的含义如所定义；其药学上可接受的前药衍生物和药学上可接受的盐；其制备方法；包含所述化合物的药物组合物；以及使用这些化合物抑制基质降解金属蛋白酶和治疗依赖于基质降解金属蛋白酶的哺乳动物病症的方法。

  公开号：

  US05646167A1
• 作为产物：
  描述：

  N-(2-氨基乙基)吗啉 在 sodium hydride 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 2.5h， 生成 Ethyl 2-[[4-methoxybenzenesulfonyl](2-[4-morpholino]ethyl)amino]acetate
  参考文献：
  名称：

  Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits

  摘要：

  Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.

  DOI：

  10.1021/jm960871c

文献信息

• Arylsulfonamido-substituted hydroxamic acids
  申请人：Ciba-Geigy Corporation

  公开号：US05455258A1

  公开（公告）日：1995-10-03

  Particularly the invention relates to the compounds of formula I ##STR1## (a) wherein Ar is carbocyclic or heterocyclic aryl; R is hydrogen, lower alkyl, carbocyclic aryl-lower alkyl, carbocyclic aryl, heterocyclic aryl, biaryl, biaryl-lower alkyl, heterocyclic aryl-lower alkyl, mono- or poly-halo-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, amino, mono- or di-lower alkylamino)-lower alkyl, acylamino-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, or (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl; R.sub.1 is hydrogen, lower alkyl, carbocyclic aryl-lower alkyl, carbocyclic aryl, heterocyclic aryl, biaryl, biaryl-lower alkyl, heterocyclic aryl-lower alkyl, mono- or poly-halo-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, (carbocyclic or heterocyclic aryl)-lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl, acylamino-lower alkyl, piperidyl or N-lower alkylpiperidyl; R.sub.2 is hydrogen or lower alkyl; pharmaceutically acceptable prodrug derivatives; and pharmaceutically acceptable salts thereof.

  该发明涉及以下式I的化合物：(a)其中Ar是碳环或杂环芳基；R是氢、低烷基、碳环芳基-低烷基、碳环芳基、杂环芳基、联苯、联苯-低烷基、杂环芳基-低烷基、单取代或多取代卤代低烷基、C.sub.3-C.sub.7-环烷基、C.sub.3-C.sub.7-环烷基-低烷基、羟基-低烷基、酰氧基-低烷基、低烷氧基-低烷基、低烷基-(硫、亚砜或砜基)-低烷基、氨基、单取代或双取代低烷氨基)-低烷基、酰胺基-低烷基、(N-低烷基哌嗪基或N-芳基-低烷基哌嗪基)-低烷基，或(morpholino、硫代吗啉、哌啶基、吡咯啶基、哌啶基或N-低烷基哌啶基)-低烷基；R.sub.1是氢、低烷基、碳环芳基-低烷基、碳环芳基、杂环芳基、联苯、联苯-低烷基、杂环芳基-低烷基、单取代或多取代卤代低烷基、C.sub.3-C.sub.7-环烷基、C.sub.3-C.sub.7-环烷基-低烷基、羟基-低烷基、酰氧基-低烷基、低烷氧基-低烷基、(碳环或杂环芳基)-低烷氧基-低烷基、低烷基-(硫、亚砜或砜基)-低烷基、(氨基、单取代或双取代低烷氨基)-低烷基、(N-低烷基哌嗪基或N-芳基-低烷基哌嗪基)-低烷基、(morpholino、硫代吗啉、哌啶基、吡咯啶基、哌啶基或N-低烷基哌啶基)-低烷基、酰胺基-低烷基、哌啶基或N-低烷基哌啶基；R.sub.2是氢或低烷基；药学上可接受的前药衍生物；及其药学上可接受的盐。
• Arylsufonamido-substituted hydroxamic acids
  申请人：Ciba-Geigy Corporation

  公开号：US05506242A1

  公开（公告）日：1996-04-09

  The invention relates to a method of inhibiting metalloellastase activity, of inhibiting the degradation of elastin, or of treating macrophage metalloelastase dependent conditions in mammals which comprises administering to a mammal in need thereof an effective macrophage metalloelastase inhibiting amount of a compound of formula I ##STR1## wherein Ar, R, R.sub.1 and R.sub.2 have meanings as defined, or of a pharmaceutically acceptable prodrug derivative thereof, or of a pharmaceutically acceptable salt thereof, or of pharmaceutical compositions comprising a said compound.

  该发明涉及一种抑制金属弹性蛋白酶活性、抑制弹性蛋白降解或治疗依赖于巨噬细胞金属弹性蛋白酶的哺乳动物病症的方法，包括向需要的哺乳动物施用化合物I的有效巨噬细胞金属弹性蛋白酶抑制剂量，其中Ar、R、R.sub.1和R.sub.2的含义如所定义，或其药学上可接受的前药衍生物，或其药学上可接受的盐，或包括所述化合物的药物组合物。
• Arylsulfonamido-substituted hydroxamix acids
  申请人：Ciba-Geigy Corporation

  公开号：US05646167A1

  公开（公告）日：1997-07-08

  Disclosed are compounds of formula I ##STR1## wherein R, R.sub.1, R.sub.2 and Ar have meanings as defined; pharmaceutically acceptable prodrug derivatives and pharmaceutically acceptable salts thereof; methods for preparation thereof; pharmaceutical compositions comprising said compounds; and methods of inhibiting matrix-degrading metalloproteinase and of treating matrix-degrading metalloproteinase dependent conditions in mammals using such compounds.

  公开的是式I的化合物##STR1##其中R、R.sub.1、R.sub.2和Ar的含义如所定义；其药学上可接受的前药衍生物和药学上可接受的盐；其制备方法；包含所述化合物的药物组合物；以及使用这些化合物抑制基质降解金属蛋白酶和治疗依赖于基质降解金属蛋白酶的哺乳动物病症的方法。
• US5455258A
  申请人：——

  公开号：US5455258A

  公开（公告）日：1995-10-03
• US5506242A
  申请人：——

  公开号：US5506242A

  公开（公告）日：1996-04-09